Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT ...
Dose 1 of PBFT02 in upliFT-D trial for FTD-GRN achieved robust CSF progranulin levels, sustained up to 12 months, and was well-tolerated with revised immunosuppression. Updated data to be presented at ISFTD2024.
Related Clinical Trials
Reference News
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT ...
Dose 1 of PBFT02 in upliFT-D trial for FTD-GRN achieved robust CSF progranulin levels, sustained up to 12 months, and was well-tolerated with revised immunosuppression. Updated data to be presented at ISFTD2024.